QIAGEN NV has received US FDA approval to market the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer. The US FDA approval of the KRAS test kit marks a milestone in QIAGEN’s global expansion of its Personalized Healthcare franchise which includes an industry-leading portfolio of molecular companion diagnostics to aid treatment decisions in oncology. QIAGEN already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.
